A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors
Status:
Terminated
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the recommended Phase II dose of nilotinib when
used in combination with cetuximab in the treatment of patients with recurrent and/or
metastatic Kras wildtype colorectal cancer or squamous cell carcinoma of the head and neck.